News & Events
- April 21, 2020
-
March 30, 2020 - March 31, 2020
POSTPONED: 2020 DIA Digital Technology in Clinical Trials Conference
The ePRO Consortium is pleased to be a co-sponsor of the upcoming 2020 DIA Digital Technology in Clinical Trials Conference to be held from March 30-31, 2020 in Boston, MA. This multi-track conference will bring together thought-leaders from regulatory agencies, biotech, pharmaceutical, patients, and academia to discuss the latest advances, challenges, and forward-thinking approaches for... -
March 26, 2020
ePRO Consortium Announces Open Access Article
In collaboration with the DIA Study Endpoints Community, C-Path’s ePRO Consortium is pleased to announce the open access article “Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials” is available online in the April 1, 2020 issue of Contemporary Clinical Trials. This article provides recommendations for the structure and content of an evidence dossier aimed at supporting a clinical trial endpoint derived from mobile sensor data as fit-for-purpose in regulatory decision making.
Link to article: https://www.contemporaryclinicaltrials.com/article/S1551-7144(20)30040-9/fulltext
-
March 19, 2020
C-Path Receives FDA Grant to Establish Rare Disease Clinical Outcome Assessment Consortium
The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research has funded a cooperative agreement to establish a Rare Disease Clinical Outcome Assessment Consortium. The grant was awarded to C-Path with the NORD as a sub-awardee. The first step taken toward the establishment of the new consortium has been the creation of the Rare Disease Subcommittee within C-Path’s Patient-Reported Outcome (PRO) Consortium.
-
March 18, 2020
C-Path and Lundbeck Announce a Data Sharing Collaboration to Enable Development of Advanced Drug Development Tools in Alzheimer’s Disease
C-Path and H. Lundbeck A/S are proud to announce that they will work together to significantly improve the scientific community’s insight in Alzheimer’s disease through Lundbeck’s contribution of a unique set of clinical trial data from more than 2,500 AD patients to the Critical Path for Alzheimer’s Disease consortium’s integrated database for qualified researchers across the globe to access.
